An2 Therapeutics, Inc. (ANTX)

$15.66

-0.42

(-2.61%)

Market is closed - opens 7 PM, 03 Oct 2023

Insights on An2 Therapeutics, Inc.

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 82.6% return, outperforming this stock by 90.1%

Performance

  • $15.51
    $16.10
    $15.66
    downward going graph

    0.96%

    Downside

    Day's Volatility :3.66%

    Upside

    2.73%

    downward going graph
  • $4.87
    $21.04
    $15.66
    downward going graph

    68.9%

    Downside

    52 Weeks Volatility :76.85%

    Upside

    25.57%

    downward going graph

Returns

PeriodAn2 Therapeutics, Inc.Index (Russel 2000)
3 Months
92.34%
0.0%
6 Months
62.26%
-1.9%
1 Year
-13.08%
6.3%
3 Years
4.42%
14.9%

Highlights

Market Capitalization
453.0M
Book Value
$4.0
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-3.49
Wall Street Target Price
24.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-32.48%
Return On Equity TTM
-53.34%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
Diluted Eps TTM
-3.49
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.36
EPS Estimate Next Year
-3.45
EPS Estimate Current Quarter
-0.85
EPS Estimate Next Quarter
-0.92

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for An2 Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 53.26%

Current $15.66
Target $24.00

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
An2 Therapeutics, Inc.
An2 Therapeutics, Inc.
7.92%
62.26%
-13.08%
4.42%
4.42%
Moderna, Inc.
Moderna, Inc.
-5.55%
-35.23%
-14.63%
50.11%
455.32%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.01%
-0.39%
11.95%
45.71%
105.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.33%
13.96%
77.36%
164.9%
284.93%
Seagen, Inc.
Seagen, Inc.
2.4%
5.02%
54.07%
9.88%
161.08%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.15%
9.93%
16.91%
33.34%
81.18%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
An2 Therapeutics, Inc.
An2 Therapeutics, Inc.
NA
NA
NA
-3.36
-0.53
-0.32
0.0
4.0
Moderna, Inc.
Moderna, Inc.
34.94
34.94
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.08
22.08
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
43.05
43.05
2.03
1.64
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.67
26.67
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
An2 Therapeutics, Inc.
An2 Therapeutics, Inc.
Buy
$453.0M
4.42%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.2B
455.32%
34.94
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.6B
105.45%
22.08
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$412.6B
284.93%
43.05
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$39.8B
161.08%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$89.7B
81.18%
26.67
35.4%

Institutional Holdings

  • RA Capital Management, LLC

    12.70%
  • Bvf Inc

    5.26%
  • Citadel Advisors Llc

    4.50%
  • TCG Crossover Management, LLC

    4.34%
  • HHG PLC

    3.37%
  • Octagon Capital Advisors LP

    2.43%

Company Information

an2 therapeutics, inc. is a california-based global health biopharmaceutical company focused on bringing the power of modern biomedical and drug development expertise to provide transformational medicines for patients suffering from infectious diseases. an2 is a mission-driven company, with a vision for humanity to be free from the threat of infectious diseases by addressing the urgent need for new treatments that can save lives across the globe. founded by a small team of biopharmaceutical industry leaders with a passion for global health and experience in infectious disease drug r&d, we strive to bring patients treatments that will restore their health and enable them to live productive lives.

Organization
An2 Therapeutics, Inc.
Employees
35
CEO
Mr. Joseph S. Zakrzewski
Industry
Services

FAQs